A novel chondrocyte sheet fabrication using human-induced pluripotent stem cell-derived expandable limb-bud mesenchymal cells
Stem Cell Research & Therapy volume 14, Article number: 34 (2023)
Cell sheet fabrication for articular cartilage regenerative medicine necessitates a large number of chondrocytes of consistent quality as a cell source. Previously, we have developed human-induced pluripotent stem cell (iPSC)-derived expandable PRRX1+ limb-bud mesenchymal cells (ExpLBM) with stable expansion and high chondrogenic capacity, while in this study; our ExpLBM technology was combined with cell sheet engineering to assess its potential as a stable cell source for articular cartilage regeneration.
ExpLBM cells derived from human-induced pluripotent stem cells (hiPSCs), including 414C2 and Ff-KVs09 (HLA homozygous), were seeded onto a culture plate and two-dimensional chondrogenic induction (2-DCI) was initiated. After 2-DCI, ExpLBM-derived chondrocytes were stripped and transferred to temperature-responsive culture inserts and the chondrocyte sheets were histologically examined or transplanted into osteochondral knee defects of immunodeficient rats.
Immunohistochemistry revealed that ExpLBM-derived cell sheets were positive for Safranin O, COL2, and ACAN but that they were negative for COL1 and RUNX2. Furthermore, the engrafted tissues in osteochondral knee defects in immunodeficient rats were stained with SafO, human VIMENTIN, ACAN, and COL2.
The present study is the first to report the chondrocyte sheet fabrication with hiPSC-derived cell source. hiPSC-derived ExpLBM would be a promising cell source for cell sheet technology in articular cartilage regenerative medicine.
Articular cartilage is made up of chondrocytes that are seen to be randomly distributed and embedded in an extracellular matrix (ECM) that is mostly made up of Type II collagen and proteoglycans. This ECM absorbs external shock and facilitates smooth articular movements [1, 2]. We see therefore that spontaneous regeneration of their defects caused by traumatic injury or osteoarthritis (OA) is difficult due to the avascular structure of articular cartilage. Where chondrocyte transplantation derived from auto- or allografts is one of the therapies used to prevent or delay OA progression [3, 4], focal cartilage defects have thus been identified as a potential risk factor for OA. Current graft approaches for small cartilage defects include osteochondral autograft transfer , osteochondral allograft transplantation , and autologous chondrocyte implantation [7, 8], however, their need for a large number of chondrocytes or limited applications restrict graft options.
Recently, chondrocyte sheets have been engineered as a therapeutic strategy for articular cartilage defects. While Sato et al. have conducted a clinical study to test the autologous transplantation of human chondrocyte sheets in knee defects of patients with OA and confirmed no serious adverse events after more than 3 years , it is seen that chondrocytes proliferate on temperature-responsive culture devices such as thermo-responsive polymer-coated culture dishes or devices [10, 11], forming sheets that can be collected by lowering the temperature. In addition, the safety and therapeutic effect of chondrocyte sheets have been demonstrated in several animal models [12,13,14,15].
Previously, we demonstrated that human-induced pluripotent stem cell (hiPSC)-derived expandable limb-bud mesenchymal cells (ExpLBM) are stably expandable while maintaining high chondrogenic capacity in xeno-free culture conditions . Human cartilage tissues in the cranial, axial, and appendicular skeletons are ontogenically generated from the neural crest, paraxial mesoderm, and lateral plate mesoderm-derived lineages, respectively [17,18,19], which implies that lateral plate mesoderm-derived ExpLBM would be a desirable cell source for the regeneration of limb articular cartilages. In this study, ExpLBM was found to produce functional and engraftable chondrocyte sheets when we combined the ExpLBM with cell sheet technology.
Materials and methods
Complete materials and methods are presented in Additional file 1: Supplemental materials and methods.
Previously, we ontogenically induced limb-bud mesenchyme (LBM) from hiPSCs and established their expansion method . Figure 1A depicts the cellular morphology of 414C2 hiPSCs at each stage of differentiation. Due to the fact that immune rejection is one of the most serious problems in regenerative medicine , HLA-homozygous hiPSCs (Ff-KVs09) were also tested in this study. ExpLBM cells derived from 414C2 hiPSCs (414C2 ExpLBM) and Ff-KVs09 HLA-homozygous hiPSCs (Ff-KVs09 ExpLBM) expressed PRRX1 and SOX9 stably (Fig. 1B), and maintained an almost 100% positive rate of SOX9 expression during serial passage (Fig. 1C).
To fabricate the ExpLBM-derived chondrocyte sheet, ExpLBM cells were first used in a two-dimensional (adhesive culture) chondrogenic induction (2-DCI) protocol with STEP1 and STEP3 medium for inducing an ExpLBM-derived chondrocyte sheet (Fig. 2A). After chondrocyte induction using the 2-DCI protocol, 414C2 ExpLBM produced several nodules stained with Alcian blue (Fig. 2B). Following 2-DCI, ExpLBM-derived chondrocytes were dissociated, reseeded on temperature-responsive culture inserts, and cultured in a sheet medium. ExpLBM-derived chondrocyte sheets with high cell density formed a thick structure with an integrated layer that was easily harvested and manipulated without tearing (Fig. 2C). RT-qPCR analysis revealed that COL2A1 and COL1A1 were significantly upregulated in 414C2 ExpLBM-derived chondrocyte sheets rather than ExpLBM cells, whereas Ff-KVs09 ExpLBM-derived chondrocytes showed significantly higher expression of COL2A1 and ACAN compared to Ff-KVs09 ExpLBM cells (Fig. 2D). Histological examination of 414C2 and Ff-KVs09 ExpLBM-derived chondrocyte sheets revealed that the cells were embedded in ECM that was intensely and homogeneously stained with Alcian blue and Safranin O. Immunohistochemistry revealed that all cells used were embedded in the ECM expressed SOX9 but not RUNX2; Type II collagen (COL2) was detected in the ECM but not COL1 (Fig. 2E). Although we found some differences among hiPSC clones in cellular characteristics of chondrocyte sheets, these findings suggest that ExpLBM-derived chondrocyte sheets exhibit hyaline cartilage-like characteristics.
To demonstrate regenerative efficacy in vivo, these ExpLBM-derived chondrocyte sheets were transplanted into osteochondral defects (1-mm drill hole × 3 defects; 1-mm depth) created in the knee joint cartilage of X-linked severe combined immunodeficiency (X-SCID) rats (Fig. 3A). Four weeks after transplantation, both 414C2 and Ff-KVs09 ExpLBM-derived chondrocyte sheets were successfully engrafted into osteochondral defects. The defects were filled with ExpLBM-derived chondrocytes, as evidenced by human vimentin (hVIMENTIN) expression. These chondrocyte sheets produced ECM, which was stained with toluidine blue and Safranin O. Immunohistochemistry revealed that COL2 and ACAN were found in numerous ECM regions of regenerated neocartilage, but COL1 was found only in the neocartilage surfaces (Fig. 3B and C). However, there were two limitations to this study. First, 4 weeks post transplantation is a short period for evaluating cartilage repair. Second, this study was conducted on immune-deficient rats. The validation of efficacy of transplantation is required in larger animals that more closely resemble humans. We plan to verify the efficacy of various cell source for ExpLBM-induced chondrocyte sheets for long time transplantation using large animals.
In this study, we successfully fabricated an ExpLBM-derived chondrocyte sheet positive for COL2 and ACAN, which can be used as a potential regenerative resource for hyaline cartilage tissues. To our knowledge, this present study is the first to report the chondrocyte sheet fabrication with hiPSC-derived cell source. Given the challenges of human cartilage-derived chondrocyte cell sources with regard to their stable expansion while chondrogenic activity is maintained, our cell source of hiPSC-derived ExpLBM has the potential to stably provide a sufficient number of human chondrocytes for cell sheet fabrication in regenerative medicine. Furthermore, where we see that HLA-homozygous hiPSC-derived ExpLBM can reduce the risk of immune rejection due to HLA mismatching, taken together, hiPSC-derived ExpLBM would be a promising cell source for cell sheet technology in articular cartilage regenerative medicine.
Expandable PRRX1+ LBM.
Human-induced pluripotent stem cells.
Two-dimensional chondrogenic induction.
Buckwalter JA, Mankin HJ. Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instr Course Lect. 1998;47:487–504.
Buckwalter JA, Mankin HJ, Grodzinsky AJ. Articular cartilage and osteoarthritis. Instr Course Lect. 2005;54:465–80.
Minas T, Gomoll AH, Solhpour S, Rosenberger R, Probst C, Bryant T. Autologous chondrocyte implantation for joint preservation in patients with early osteoarthritis. Clin Orthop Relat Res. 2010;468(1):147–57.
de Windt TS, Vonk LA, Brittberg M, Saris DB. Treatment AND prevention of (Early) osteoarthritis using articular cartilage repair-fact or fiction? A systematic review Cartilage. 2013;4(3 Suppl):5S-12S.
Hangody L, Dobos J, Balo E, Panics G, Hangody LR, Berkes I. Clinical experiences with autologous osteochondral mosaicplasty in an athletic population: a 17-year prospective multicenter study. Am J Sports Med. 2010;38(6):1125–33.
Hangody L, Rathonyi GK, Duska Z, Vasarhelyi G, Fules P, Modis L: Autologous osteochondral mosaicplasty. Surgical technique. J Bone Joint Surg Am 2004;86-A Suppl 1:65–72.
Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. 1994;331(14):889–95.
Saris DB, Vanlauwe J, Victor J, Almqvist KF, Verdonk R, Bellemans J, et al. Treatment of symptomatic cartilage defects of the knee: characterized chondrocyte implantation results in better clinical outcome at 36 months in a randomized trial compared to microfracture. Am J Sports Med. 2009;37(Suppl 1):10S-19S.
Sato M, Yamato M, Mitani G, Takagaki T, Hamahashi K, Nakamura Y, et al. Combined surgery and chondrocyte cell-sheet transplantation improves clinical and structural outcomes in knee osteoarthritis. NPJ Regen Med. 2019;4:4.
Okano T, Yamada N, Okuhara M, Sakai H, Sakurai Y. Mechanism of cell detachment from temperature-modulated, hydrophilic-hydrophobic polymer surfaces. Biomaterials. 1995;16(4):297–303.
Okano T, Yamada N, Sakai H, Sakurai Y. A novel recovery system for cultured cells using plasma-treated polystyrene dishes grafted with poly(N-isopropylacrylamide). J Biomed Mater Res. 1993;27(10):1243–51.
Takaku Y, Murai K, Ukai T, Ito S, Kokubo M, Satoh M, et al. In vivo cell tracking by bioluminescence imaging after transplantation of bioengineered cell sheets to the knee joint. Biomaterials. 2014;35(7):2199–206.
Takahashi T, Sato M, Toyoda E, Maehara M, Takizawa D, Maruki H, et al. Rabbit xenogeneic transplantation model for evaluating human chondrocyte sheets used in articular cartilage repair. J Tissue Eng Regen Med. 2018;12(10):2067–76.
Ito S, Sato M, Yamato M, Mitani G, Kutsuna T, Nagai T, et al. Repair of articular cartilage defect with layered chondrocyte sheets and cultured synovial cells. Biomaterials. 2012;33(21):5278–86.
Kaneshiro N, Sato M, Ishihara M, Mitani G, Sakai H, Mochida J. Bioengineered chondrocyte sheets may be potentially useful for the treatment of partial thickness defects of articular cartilage. Biochem Biophys Res Commun. 2006;349(2):723–31.
Yamada D, Nakamura M, Takao T, Takihira S, Yoshida A, Kawai S, et al. Induction and expansion of human PRRX1(+) limb-bud-like mesenchymal cells from pluripotent stem cells. Nat Biomed Eng. 2021;5(8):926–40.
Berendsen AD, Olsen BR. Bone development. Bone. 2015;80:14–8.
Tam WL, Luyten FP, Roberts SJ. From skeletal development to the creation of pluripotent stem cell-derived bone-forming progenitors. Philos Trans R Soc Lond B Biol Sci 2018;373(1750).
Prummel KD, Nieuwenhuize S, Mosimann C; The lateral plate mesoderm. Development 2020;147(12).
Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell 2019, 24(4):566–578 e567.
The authors would like to thank the members of the Central Research Laboratory at Okayama University Medical School for their technical assistance.
This work was supported in part of the research design and analysis by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (grant no. 21H02643 to T. Takarada*) and AMED (grant no. 18bm0704024h0001 to T. Takarada*, JP20lm0203008 and JP21lm0203008 to DY).
Ethics approval and consent to participate
The Ethics Committee of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, approved the experimental protocols for studies of human subjects about using human pluripotent stem cells (project title; Molecular analysis of the process of human skeletal development using human iPS cells, approval number; K1707-013, date of approval; December 6, 2019).
Consent for publication
Availability of data and materials
All data generated or analyzed during this study are included in this article.
T. Takao, DY, and T. Takarada have a patent pending related to this work (PCT/JP2020/03551). MS perceives funding from CellSeed Inc. MS is one of the inventors on the patents (PCT/JP2006/303759, PCT/JP2017/031136) held by the applicants Tokai University and CellSeed Inc. for the manufacturing process of chondrocyte sheets. Other authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Takao, T., Sato, M., Fujisawa, Y. et al. A novel chondrocyte sheet fabrication using human-induced pluripotent stem cell-derived expandable limb-bud mesenchymal cells. Stem Cell Res Ther 14, 34 (2023). https://doi.org/10.1186/s13287-023-03252-4